International agreement on pandemics adopted at the WHO

By The New Obs with AFP

Published on May 20, 2025 at 11:19 a.m. , updated on May 20, 2025 at 1:41 p.m.

Google News

Reading time: 3 min.

After more than three years of tough negotiations, a historic international agreement on the prevention and control of pandemics was adopted this Tuesday, May 20, at the World Health Organization (WHO).

Also read

Interview Five years since Covid-19: “We must avoid a war of remembrance between victims”

"This agreement is a victory for public health, science, and multilateral action. It will allow us, collectively, to better protect the world against future pandemic threats," WHO chief Tedros Adhanom Ghebreyesus said in a statement. "Today is a great day […] it is a historic day," he told AFP.

The text, adopted at the annual meeting of the World Health Organization's member states, establishes earlier and more effective global coordination to prevent, detect, and respond more quickly to pandemic risks, following the collective failure to combat Covid-19 , which has killed millions and devastated the global economy.

Affordable vaccines

A success after often difficult and razor-thin negotiations, in a context of drastic cuts to the WHO budget , despite the fact that it is facing ever-increasing crises. The resolution on the agreement was adopted in committee on Monday evening by 124 votes in favor and no votes against. Among the countries that abstained were Iran, Israel, Russia, Italy, Slovakia, and Poland.

Although the US withdrawal from the WHO , decided by Donald Trump after his return to the White House, is not expected to take effect until January, the United States had already withdrawn from the negotiations in recent months. And the country did not send any delegates to the assembly.

Also read

"The Covid-19 pandemic has been an electroshock. It has brutally reminded us that viruses know no borders, that no country, however powerful, can face a global health crisis alone," noted Anne-Claire Amprou, France's ambassador for global health, who co-chaired the negotiations. The agreement aims to guarantee equitable access to health products in the event of a pandemic. The issue had been at the heart of many grievances among poorer countries during the Covid-19 pandemic, when they saw rich countries appropriating vaccine doses and other tests.

Negotiations have long stumbled over key issues such as pandemic surveillance and the sharing of data on emerging pathogens and the benefits they generate, including vaccines, tests, and treatments . At the heart of the agreement is a new "pathogen access and benefit sharing" (PABS) mechanism, which is intended to enable "very rapid and systematic sharing of information on the emergence of pathogens with pandemic potential," according to Anne-Claire Amprou.

Each pharmaceutical company that agrees to participate in the mechanism will have to, in the event of a pandemic, make available to the WHO "rapid access to a targeted percentage of 20% of its real-time production of safe vaccines, therapeutics and diagnostics," including a "minimum of 10%" as a donation and the remaining percentage "at an affordable price ." The practical details of the mechanism - considered the jewel of the agreement - still need to be negotiated, within the next one to two years, before the agreement can be ratified. Sixty ratifications will be needed for the treaty to enter into force.

Also read